diabetic nephropathy
Conditions
Interventions
diet therapy group
standard therapies group (pravastatin 10mg)
active treatment group (atorvastatin 10mg)
Sponsors
Fukuiken-Saiseikai Hospital
Kanazawa University School of Medicine Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1 Age is 18 years old-80 years old, and sexuality is no object 2 A minor or middle-class nephropathic definition: following conditions more than once at the same time 1)serum creatinine concentration 0.9-1.5mg/dl 2)urinary albumin positive or urine protein (qualitative analysis) is more than 3)Calculation method of LDL-C value: It depends on either of Freidwald method (equal to or less than TG 400mg/dl)or direct technique 4)The case that an agreement in a document is obtained than the person himself in becoming a subject of the final examination.
Exclusion criteria
Exclusion criteria: 1 While person take statins, or statins administration is done one within three months 2 160/100mm Hg is more than most recent twice sphygmomanometry value together the one where blood pressure control is poor 3 Drifting for three months is higher than 2% more than most recent HbA1c10% recently the one where glycemic control states are defectiveness or insecurity 4 The one that presents nephrotic syndrome 5 The person who judged that others, a family doctor were inadequate 6 Others, Dr.clinical study liability or Dr.clinical study allotment is this clinical study which they intend for it and judged to be inadequate
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Prospective Study of the Effects of Cholesterol-lowering therapy in Between 3 group ( diet therapy group, standard therapies group (pravastatin 10mg), iactive treatment group(atorvastatin10mg )on Progression of diabetic nephropathy. | — |
Secondary
| Measure | Time frame |
|---|---|
| 1)Nephropathic analysis in before and after about chemical administration 2)Analysis of LDL-C in before and after about this chemical administration 3)Comparison in diet therapy,atorvastatin,pravastatin in superscription | — |
Countries
Japan
Contacts
Public ContactTakazakura Akiko
Internal secretion metabolism internal medicine internal medicine
Outcome results
None listed